How Can I Get Eliquis Cheap from BMS Pfizer?

Introduction to Eliquis

• Eliquis is a drug that is prescribed as an oral anticoagulant to prevent blood clots, particularly for patients with atrial fibrillation. It contains the active ingredient, Apixaban. Patients who have been prescribed Eliquis benefit from its proven effectiveness in reducing clot-related risks.
• Eliquis is coming off patent in 2026, with at least eight generic copies expected to launch in April 2028.
• The BMS-Pfizer alliance offers Eliquis as a direct-to-patient option, providing important health benefits through significant savings. In the U.S., the high number of prescriptions for Eliquis highlights its widespread adoption and importance in patient care.
• As a leading pharmaceutical company, Bristol Myers Squibb and Pfizer prioritize access to their medication, ensuring patients can purchase Eliquis at a discounted rate. This direct-to-patient approach is similar to strategies used by Novo Nordisk in the pharmaceutical industry, where direct engagement with patients is key to improving access. Christopher Boerner, Bristol Myers Squibb’s CEO and board chair, has publicly stated the company’s commitment to improving patient access and affordability for Eliquis.
• The medicine is used by Americans daily to reduce the risk of blood clots and other related health issues. Eliquis is the nation’s number one prescribed oral anticoagulant, underscoring its significance in the U.S. healthcare system.
• Eliquis is also used to treat deep vein thrombosis and pulmonary embolism, making it an important medication option for many patients.

Image showing a pack of 100 tablets of Eliquis 5mg

Discount Program Details

• The BMS-Pfizer alliance offers a direct-to-patient program, allowing eligible U.S. patients to purchase Eliquis at a discounted price, significantly lower than the current list price.
• Patients can expect to receive a discount of up to 40% on the market price of Eliquis.
• The program provides direct shipping to all 50 states and Puerto Rico, making it easily accessible to patients across the nation. This means the program can provide direct shipping of the medicine directly to patients’ homes for added convenience.
• The discount program is designed for self-pay patients and cash-paying patients, offering more savings and reducing out-of-pocket costs. The program also allows for purchasing Eliquis directly from the manufacturer, streamlining access for those without insurance.
• The alliance’s patient resource, Eliquis 360 Support, serves as the alliance’s patient resource by providing health education, insurance navigation, and increasing patient access to the medication through direct-to-patient purchasing options.
• By offering Eliquis directly to patients, the BMS-Pfizer alliance aims to provide a simple and transparent way to purchase the medication, passing savings directly to patients. The negotiated price for Eliquis under the Inflation Reduction Act and Medicare will further impact affordability for beneficiaries. Compared to other developed countries, U.S. drug pricing strategies are evolving, and this program responds to international pricing trends to improve access and affordability.
• Eliquis is still available at no cost for eligible patients under the Bristol-Myers Squibb Patient Assistance Foundation. You can also check your eligibility for Eliquis patient assistance through the prescription discount programs page on NowPatient.

Eligibility Requirements for Eliquis Discounts

To be eligible for the Eliquis discounts offered through the direct-to-patient program, patients must meet specific requirements. The program, launched by the Bristol Myers Squibb and Pfizer alliance, aims to provide affordable access to Eliquis, a prescribed oral anticoagulant, for self-pay patients, uninsured, and underinsured individuals.

Patients must have a valid Eliquis prescription to participate in the program. The alliance’s patient resource, Eliquis 360 Support, will facilitate the process, offering a simple and transparent way for patients to purchase Eliquis at a discounted rate. This rate is more than 40% below the current list price, significantly lowering out-of-pocket costs for eligible U.S. patients.

The program passes more savings directly to patients, focusing on identifying innovative solutions to foster the best outcomes. By providing direct shipping across all 50 states and Puerto Rico, the BMS-Pfizer Alliance ensures convenient access to this critical blood thinner. The initiative reflects a continued focus on prioritizing access and affordability, aligning with the goals of the Inflation Reduction Act to negotiate lower drug prices.

To qualify, patients should not have insurance coverage that fully covers the cost of Eliquis or should be cash-paying patients. The program is designed to help those who cannot afford the medication at its full price, ensuring that more Americans can benefit from this important medication. By offering a discounted price and direct shipping, the alliance increases patient access to Eliquis, which is the nation’s number one prescribed oral anticoagulant for reducing the risk of blood clots and stroke in patients with atrial fibrillation.

The patient support program, Eliquis 360 Support, also provides health education and assistance with navigating prescription insurance coverage, further supporting patients in managing their condition effectively. This direct-to-patient offering is part of a growing trend among pharmaceutical companies like Bristol Myers Squibb and Pfizer to improve patient access and affordability, making essential medications like Eliquis more accessible to those who need them.

Accessing Affordable Eliquis

• Eligible patients can access the discounted Eliquis program by visiting the BMS-Pfizer website or contacting their patient support program directly.
• The program is part of a growing trend among pharmaceutical companies to offer direct-to-patient sales, increasing patient access and affordability.
• By identifying innovative solutions, Bristol Myers Squibb and Pfizer continue to prioritize access to their medication, ensuring patients can receive the best outcomes.
• The new program offers a discounted rate for Eliquis, providing significant savings for uninsured and underinsured patients and reducing the financial burden of purchasing the medication.
• Patients can expect to pay a significantly lower price for Eliquis through the program, compared to the current list price, making it more accessible to those who need it.

Is the new Eliquis Program price cheaper than the Medicare negotiated price?

Eliquis obtained directly through the new program for cash-paying patients is $346 for a 30-day supply. This represents a 43% discount off the list price of $606.

Everything said, the $346 direct-to-consumer price is still 50% higher than the $231 price that Medicare negotiated for Eliquis during the first round of negotiation in Medicare’s new drug price negotiation program, under the Inflation Reduction Act.

As an aside, if you have commercial insurance, then there is a manufacturer-sponsored coupon that makes the drug available for only $10 monthly copay.